

Plaintiffs,  
v.  
AMNEAL PHARMACEUTICALS, LLC, *et al.*,  
Defendants.

Civil Action No. 13-391 (ES)(JAD)  
(Consolidated)

(Filed Electronically)

**ORDER**

THIS MATTER having been brought before the Court upon the application of Plaintiffs Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Ltd. (collectively, “Jazz”) (D.I. 374, 389, 395) seeking an order compelling certain discovery from Defendants Lupin Limited, Lupin Pharmaceuticals, Inc. and Lupin Inc. (collectively, “Lupin”); and the Court having considered the submissions of Jazz and Lupin in support of and in opposition to the application; and having heard the arguments of counsel on March 2, 2018; and for good cause shown:

IT IS on this <sup>th</sup> 19<sup>th</sup> day of March, 2018,

**ORDERED THAT:**

Jazz’s request for an Order compelling Lupin to produce certain discovery is **GRANTED**


**IN PART;**

And it is **FURTHER ORDERED THAT:**

Lupin shall promptly produce the following discovery to Jazz:

appropriate redactions for relevance to the extent that the missing pages for Lab Notebook 1427 concern products other than sodium oxybate;

- All FDA correspondence concerning a generic Risk Evaluation and Mitigation Strategy for sodium oxybate in Lupin's possession, custody, and control, with appropriate redactions for privilege;
- A Rule 30(b)(6) deposition witness(es) prepared to give testimony consistent with the parties' discussion and the Court's ruling during the March 2, 2018 conference; and
- Samples of any new batches of Lupin's sodium oxybate Abbreviated New Drug Application product, to the extent Lupin or any third party working on Lupin's behalf manufactures same.



---

**HON. JOSEPH A. DICKSON**  
**United States Magistrate Judge**

cc: Hon. Esther Salas, U.S.D.J.